Acute disseminated encephalomyelitis future or investigational therapies: Difference between revisions
m Changes made per Mahshid's request |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Acute disseminated encephalomyelitis}} | {{Acute disseminated encephalomyelitis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Sujaya}} | ||
==Overview== | |||
The use of emerging [[therapies]] has not been reported in patients with [[acute]] [[demyelinating]] [[diseases]] like [[ADEM]]. | |||
==Future or [[Investigational]] [[Therapies]]== | |||
The use of emerging [[therapies]] has not been reported in patients with [[acute]] [[demyelinating]] [[diseases]] like [[ADEM]]. | |||
==References== | ==References== | ||
Revision as of 09:48, 22 November 2022
|
Acute disseminated encephalomyelitis Microchapters |
|
Differentiating Acute disseminated encephalomyelitis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute disseminated encephalomyelitis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Acute disseminated encephalomyelitis future or investigational therapies |
|
FDA on Acute disseminated encephalomyelitis future or investigational therapies |
|
CDC on Acute disseminated encephalomyelitis future or investigational therapies |
|
Acute disseminated encephalomyelitis future or investigational therapies in the news |
|
Blogs on Acute disseminated encephalomyelitis future or investigational therapies |
|
Directions to Hospitals Treating Acute disseminated encephalomyelitis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]
Overview
The use of emerging therapies has not been reported in patients with acute demyelinating diseases like ADEM.
Future or Investigational Therapies
The use of emerging therapies has not been reported in patients with acute demyelinating diseases like ADEM.